



## Publikationen 2012

### ANKÜNDIGUNGEN

Feldt, S., Schüssel, K., Quinzler, R., Franzmann, A., Czeche, S., Ludwig, W.-D. und Schulz, M.:  
**INCIDENCE OF THYROID HORMONE THERAPY IN PATIENTS TREATED WITH SORAFENIB OR SUNITINIB: A COHORT STUDY** (zur  
Publikation eingereicht).

Letzte Änderung: 25.01.2012

### TREATMENT DURATION (PERSISTENCE) OF BASAL INSULIN SUPPORTED ORAL THERAPY (BOT) IN TYPE 2 DIABETIC PATIENTS: COMPARISON OF INSULIN GLARGINE WITH NPH INSULIN.

Int J Clin Pharmacol Ther. 2012 Jan;50(1):24-32.

PubMed-Link: <http://www.ncbi.nlm.nih.gov/pubmed?term=quinzler%20bot%202012> (DOI: 10.5414/CP201572).

→ Quinzler R<sup>a</sup>, Ude M<sup>a,b</sup>, Franzmann A<sup>a</sup>, Feldt S<sup>a</sup>, Schüssel K<sup>a</sup>, Leuner K<sup>b</sup>, Müller WE<sup>b</sup>, Dippel FW<sup>c</sup>, Schulz M<sup>a,b,d</sup>

<sup>a</sup> DAPI German Institute for Drug Use Evaluation, Eschborn,

<sup>b</sup> Department of Pharmacology, Goethe-University Frankfurt, Frankfurt am Main,

<sup>c</sup> Sanofi-Aventis Deutschland GmbH,

<sup>d</sup> ABDA Federal Union of German Associations of Pharmacists, Berlin, Germany

*Conflict of Interest: RQ, AF, SF, KS, MS: This investigation of the DAPI - German Institute for Drug use Evaluation has been financially supported by Sanofi-Aventis Deutschland GmbH, Berlin, in the years 2008 and 2009. RQ: Results of this study have been presented at the 12th Annual European ISPOR-Congress in Paris (October 24 - 27, 2009), the 16th annual meeting of the Gesellschaft für Arzneimittel-epidemiologie (GAA) e. V. in Berlin (November 19 - 20, 2009), and the 70th scientific sessions of the American Diabetes Association in Orlando (June 25 - 29, 2010). Registration fees and travel costs have been paid by Sanofi-Aventis Deutschland GmbH. MU, KL, WEM: None. FWD: Employee of Sanofi-Aventis Deutschland GmbH, Berlin.*

Letzte Änderung: 25.01.2012

**Hinweis:** Für die Ansicht der PDF Dokumente wird der Acrobat Reader benötigt. Klicken Sie auf die Grafik, um ihn herunterzuladen.

